Default company panoramic image

Respiratory Motion, Inc.

RMI has developed the first non-invasive respiration monitor to meet clinical needs for advanced-warning indication of respiratory failure.

  • Stage $500K in TTM Revenue
  • Industry Medical Devices and Equipment
  • Location Waltham, MA, USA
  • Currency USD
  • Founded March 2010
  • Employees 20
  • Website

Company Summary

Respiratory Motion is a medical device company focusing on the development and commercialization of innovative devices to monitor respiratory variation. Our lead product is the first non-invasive, point-of-care monitor to deliver a real-time, quantitative measurement of the adequacy of breathing and provide early indication of deteriorating or inadequate respiration in advance of adverse events and in advance of existing technologies.


  • Default avatar
    Jenny Freeman
    President and CEO

    25 years of experience in thoracic surgery, research, and medical device entrepreneurship, bringing products from concept through FDA approval and into the marketplace.

  • Default avatar
    Alexander Panasyuk

    25 years leading engineering teams. Long expertise in medical devices commercialization. Harvard Smithsonian Astrophysics. Moscow Institute of Physics & Tech (PhD). He is an author on all of Respiratory Motion's patent applications.

  • Default avatar
    Kamen Bliznashki
    VP Finance

    Medical device M&A experience at Deutsche Bank with Respironics / Philips, Aspect, ResMed, Smith & Nephew. Harvard Business School (MBA)

  • Default avatar
    Svetlana Panasyuk
    VP Software and Algorithm Development

    22 years of experience managing teams of engineers in research & data analysis in medical product companies

  • Default avatar
    Malcolm Bock
    VP Engineering

    25 years commercialization experience (Covidien – led engineering for $400M compression boot business, Siemens)

  • Default avatar
    Daniel McGuinness
    National Director of Sales

    15 years in sales of monitoring technologies in anesthesia (Oridion $360M exit; and Covidien)

  • Default avatar
    Paul Coss
    VP Business Development

    25 years experience in critical care and clinical informatics (Philips - Director of Marketing, Critical Care Division, HP)


  • Default avatar
    James Remenick - Remenick PLLC, Howard Rosenblum - DLA Piper
    Default avatar
    Chantal Rowat, CFA

Previous Investors

  • Default avatar
    Cherrystone, Golden Seeds, Walnut, Boston Harbor, Boynton, eCoast, Angel Investment Forum, Maine
    Default avatar
    Ariel Savanah Angels, Beta Fund, Central Illinois Angels, Jenny Freeman, Jean Hammond
    Default avatar
    Grants: Qualifying Therapeutic Discovery Project, Mass Life Science Intern Program